Stability indicating HPLC method for simultaneous estimation of emtricitabine, tenofovir disoproxyl fumarate, cobicistat and elvitegravir in pharmaceutical dosage form
A new HPLC method was developed and validated for the determination of Emtricitabine, Tenofovir disoproxyl fumarate, Cobicistat, Elvitegravir in tablet dosage form. The chromatographic separation was achieved on a Inertsil ODS 3V(4.0 x 250mm, 5m,) with a mobile phase combination of 0.1%TFA and Acetonitrile in gragient mode employing at a flow rate of 1.2 ml/min, and the detection was carried out by using UV detector at 242 nm. The total run time was 12 minutes. The retention time of Emtricitabine, Tenofovir disoproxyl fumarate, Cobicistat, Elvitegravir were found to be 3.43 min., 4.75 min., 5.27, and 7.56 min. respectively. The performance of the method was validated according to the present ICH guidelines.
Full Text Attachment